Editorial: EBV strategies to counteract the immune response

Category	Detail
Condition	Epstein-Barr Virus (EBV) Infection
Key Mechanisms	Immune evasion through manipulation of antigen presentation, induction of immunosuppressive cytokines, and upregulation of immune checkpoints.
Target Population	Individuals infected with EBV, including children and adolescents with EBV-associated diseases.
Care Setting	Research on immune responses and therapeutic strategies in EBV-related conditions.

EBV establishes lifelong, largely asymptomatic infections in over 95% of the global population.
EBV employs mechanisms like LMP1 and EBNA1 to evade immune responses.
NKG2A receptor targeting may restore NK-cell-mediated control in EBV-positive lymphomas.
Myeloid-derived suppressor cells (MDSCs) may serve as biomarkers of disease activity in EBV infections.
Early recognition and treatment of EBV-associated hemophagocytic lymphohistiocytosis (HLH) can improve outcomes.

Consider EBV infection in patients presenting with HLH and lymphoproliferative disorders.

Monitor specific MDSC subpopulations as potential biomarkers of immune dysregulation.

EBV infection can lead to various malignancies, including aggressive NK-cell leukemia and inflammatory follicular dendritic cell sarcoma.

Children and adolescents with primary and persistent EBV infection.

Therapeutic strategies may include immunotherapy targeting NK-cell receptors and antiviral agents.

Recognize the complex interplay between EBV and host immune responses.
Utilize immunophenotyping to assess MDSC dynamics in EBV infections.
Implement timely interventions for EBV-associated HLH to mitigate cytokine storms.